Introduction {#s1}
============

A variety of genetic and epigenetic alterations have been described in prostate cancer. Numerous studies have found consistent patterns of copy number alterations such as loss of 8p and 13q14 and gain of 8q24 in clinically localized and advanced prostate cancers [@pone.0032708-Sun1], [@pone.0032708-Taylor1]. Epigenetic alterations such as methylation are also common in prostate cancer. In contrast, most studies to date have shown only infrequent clonal point mutations in clinically localized prostate cancer [@pone.0032708-Taylor1], [@pone.0032708-Dong1]. In more advanced prostate cancers, clonal point mutations of tumor suppressor genes such as PTEN [@pone.0032708-Suzuki1] and p53 [@pone.0032708-Dong1] are more common, in contrast to the low frequency of mutation of these genes in localized cancer [@pone.0032708-Ittmann1], [@pone.0032708-Wang1], but are still not common compared to most malignancies. Activating clonal mutations in oncogenes, such as RAS, are not common in prostate cancer in the US [@pone.0032708-Dong1], in contrast to the more frequent mutation observed in other common human cancers such as colon and lung cancer. Clonal androgen receptor mutations are seen in castrate resistant prostate cancer and appear to be selected for as a mechanism by which prostate cancer cells can survive in low androgen environment [@pone.0032708-Dong1]. Thus available data indicate that clonal point mutations, particularly of oncogenes, are rare in clinically localized prostate cancer.

GGAP2 (also known as PIKE-A) is a G-protein which has a strong GTPase activity, as expected from its RAS homology domain. It also contains a GAP domain can activate the GTPase activity via either intramolecular or intermolecular interaction. GGAP2 binds to activated AKT and strongly enhances its activity and this interaction is promoted by GTP binding [@pone.0032708-Ahn1]. We have shown that activated AKT can bind and phosphorylate GGAP2 at serine 629, which enhances GTP binding by GGAP2 and AKT activation [@pone.0032708-Cai1]. Phosphorylated GGAP2 can also bind the p50 subunit of NFkB and enhances NFkB transcriptional activity. Increased activation of the phosphatidyl-inositol-3 kinase/AKT and NFkB pathways have both been identified as critical pathways in cancer initiation and progression in a variety of human malignancies, including prostate cancer. We have demonstrated significantly increased expression GGAP2 in the majority of human prostate cancers [@pone.0032708-Cai1]. When GGAP2 is expressed in prostate cancer cells it enhances proliferation, focus formation in vitro and tumor progression in vivo. Thus increased GGAP2 expression, which is present in three quarters of human prostate cancers, can activate two critical pathways that have been linked to prostate cancer initiation and progression and can enhance tumor progression in vivo.

Hu et al have identified mutant forms of GGAP2 in sarcoma, neuroblastoma and glioblastoma cell lines [@pone.0032708-Hu1]. In vitro studies show these mutant forms have enhanced GTPase activity and more strongly activate AKT than wild-type GGAP2. Consistent with these observations the GGAP2 mutants promote growth of glioblastoma cells and transformation of NIH3T3 cells [@pone.0032708-Liu1]. We therefore sought to identify mutations of GGAP2 in human prostate cancer samples. We have found high frequencies of missense GGAP2 mutations in clinically localized human prostate cancer. Surprisingly, the mutations are heterogeneous and nonclonal, with multiple different mutations being present in many tumors. The presence of these mutations was associated with aggressive clinical behavior and increased AP-1 transcriptional activity. Thus, GGAP2 is the most commonly mutated oncogene in human prostate cancer to date but the mutations are heterogeneous rather than clonal, implying marked clonal heterogeneity in clinically localized human prostate cancers. The presence of high frequency nonclonal mutations of a single gene is novel and represents a new mode of genetic alteration that can promote tumor progression.

Results {#s2}
=======

Mutation analysis of the GAP domain of GGAP2 {#s2a}
--------------------------------------------

To determine if GGAP2 is mutated in prostate cancer we initially focused on the GAP domain, since this region is an important negative regulator of GGAP2 activity. We analyzed cDNAs from 15 cancers and 9 benign prostate tissues from radical prostatectomy specimens. The GAP domain was amplified and individual clones were isolated and sequenced. [Results](#s2){ref-type="sec"} are shown in [Table 1](#pone-0032708-t001){ref-type="table"}. Twelve of fifteen cancer cases had at least one clone with a GGAP2 missense and/or stop mutations while only 2 of 9 benign cases had such mutations. The benign cases had only a single mutant clone each while up to 42 percent of clones in the cancer cases were mutated. Overall 38 of 206 clones from the cancer tissues were mutant versus 2 of 137 in benign. This difference was highly statistically significant (p\<0.001, chi square). To rule out an artifact due to reverse transcription or the possibility that mutant transcripts may be transcribed preferentially or have increased stability we directly analyzed the GAP domain in genomic DNAs from 46 cancers and 22 benign tissues. As shown in [Table 1](#pone-0032708-t001){ref-type="table"}, 20 of 46 cancer tissues contained at least one mutant clone and in 12 of 46 cancer tissues more than 30% of clones contained missense or stop mutations. Only a single mutant clone was identified from the benign tissues. Overall, 52 of 334 clones from the cancer tissues were mutant versus 1 of 167 from the benign tissues (p\<0.001, chi square). Combining cDNA and genomic analysis, 32 of 61 cancer cases contained clones with GAP domain mutations and in 14 cases 30% or more of the clones were mutant.

10.1371/journal.pone.0032708.t001

###### Mutation analysis of the GAP domain of GGAP2 in prostate cancer.

![](pone.0032708.t001){#pone-0032708-t001-1}

  cDNA                                                        [Missense]{.ul}           [Stop]{.ul}
  ------------- -------- ---- --- ---- ------------- ------- ----------------- ------- -------------
  7357           Cancer   19   8   42      E656G      V711M        I589F        S584A  
                                           L624P      E696G        L630P                   W703X
  1954                    17   5   29      L624M      E672G        L643P        S705T  
                                          AS692G                                       
  11686                   20   4   20   S666P/K681E   N648S     G594R/L632W            
  10420                   12   4   33      R653C      A705G        R679H        V711M  
  11147                   14   3   21      D649G      I678T        T640A               
  9523                    18   3   17      G621D      G594E     A580V/A607T            
  6882                    14   3   21      L641P      A645D                                Q709X
  6098                    7    2   29      D710V      L702P                            
  6511                    10   2   20      R662C      T622I                            
  3689                    12   2   17      T599P      L686P                            
  8032                    13   1   8       C593R                                       
  12375                   13   1   8       L698P                                       
  97             Benign   16   1   6       S670P                                       
  11627                   16   1   6       L620V                                       
  **Genomic**                                                                          
  19334          Cancer   8    5   63      E638G      W600R        I611V        E612K  
                                           A721V                                       
  27312                   8    4   50      A663P      Q707R        I581V        V576A  
  11537                   9    4   44      D633G      Q684R        S625P        A651G  
  23536                   10   4   40      N648Y      V591L        G586R        Q707R  
  47974                   9    4   44      E612V      V642G        I646L        L639M  
  17557                   6    3   50      K664Q      I609T        G621C               
  6337                    7    3   43      T659A      I609T        A651G               
  20088                   7    3   43      S657G      V706M        I611V               
  17125                   8    3   38      I581V      R582P        I581V               
  18099                   10   3   30      K664Q      H623R     A607V/E696G            
  22766                   10   3   30      E612Q      G621S        S602N               
  18062                   10   3   30      S692G      T569A        A544T               
  10702                   7    2   29      Y682C      Q707R                            
  21918                   8    2   25      A708V      A708V                            
  8665                    10   1   10   W600L/S629L                                    
  27804                   8    1   12   N652I/L686P                                    
  29823                   8    1   12      R653C                                       
  26065                   6    1   17      S629P                                       
  24069                   10   1   10      D592G                                       
  29886                   10   1   10                                                      Q707X
  25909          Benign   9    1   11      T659A                                       

Missense and stop mutations cancer and benign tissues are shown using the format: normal amino acid/amino acid number in GGAP2/mutant amino acid. An X indicates a stop mutation. Only tissues with missense or stop mutations are shown.

Surprisingly we found that the missense mutations were highly heterogeneous. There were no recurrent missense mutations involving more than two tumors. In tissues with multiple mutant clones there were only two cases with two identical mutant clones. There was variability in the distribution of the missense mutations with the regions between amino acids 640--660 and 700--710 having relatively more frequent mutations while mutations were uncommon from amino acids 540--570 but there was no statistically significant "hot spots". In several clones we found 2 mutations in the same clone. This is similar to the observation of Hu et al [@pone.0032708-Hu1], who found multiple mutations in several mutant GGAP2 cDNAs isolated from sarcoma and glioblastoma cell lines. In addition to the multiple missense mutations, we observed 3 stop mutations, all at the carboxy terminal portion of the GAP domain (aa 703--709) which is located toward the carboxy terminus of the GGAP2 protein and would result in a truncated protein. Of note, Hu et al [@pone.0032708-Hu1] found a truncation at amino acid 756 in the GGAP2 cDNA from CRL-2098 osteosarcoma cells.

Given this surprising heterogeneity we considered the possibility that this may represent a PCR misincorporation artifact. However, we found only 3 silent mutations among 540 clones from cancer tissues (versus 90 missense or stop) while in the benign tissues we found 2 silent mutations among 304 clones (versus 3 missense mutations). The proportion of missense and stop versus silent mutation was much higher in the cancer tissue than in the benign tissue and the difference was statistically significant (p = 0.02, Fisher exact test). This is inconsistent with a random misincorporation. To further examine this point, we systematically determined the consequences of transition mutations on amino acid sequence for all nucleotides in the GAP domain. We only examined transitions since 82% of the observed mutations were transition mutations (data not shown). Systematic transition mutation of each nucleotide in the GAP domain would yield 273 missense, 15 stop mutations and 162 silent mutations. The difference in the proportions of missense and stop versus silent mutations we observed (90 and 3) compared the predicted distribution (288 and 167) was highly statistically significant (p\<0.001, chi sq). Finally, we considered the possibility that the cancer tissues had an increase rate of mutation targeting the first and second bases of each codon resulting in random missense mutation in all genes. We therefore examined 5 cancer and 5 benign tissues for mutations in β-actin. We found no mutations in 32 clones from cancer tissue and 36 clones from benign tissues. The proportion of missense and stop clones in GGAP2 was statistically significantly higher than in β-actin (p = 0.02, chi sq). Thus the observed heterogeneous mutations in the GAP domain of GGAP2 are indeed genuine.

Mutation analysis of the GTPase domain of GGAP2 {#s2b}
-----------------------------------------------

The GTPase domain is also a key regulator of GGAP2 activity. We therefore examined cDNAs from 23 cancers and 12 benign tissues for GTPase domain mutations. The results were very similar to those observed with GAP domain ([Table 2](#pone-0032708-t002){ref-type="table"}). Fifteen of 23 cancers contained missense mutations versus 1 of 12 benign tissues. In four cancer cases, 40% or more of clones were mutant, while only a single mutant clone was observed in the benign tissue. Overall, 28 of 188 clones from the cancer tissues were mutated versus 1 of 88 in benign tissue (p\<0.001, chi sq). The overall pattern of mutations in the cancer tissue was similar to the GAP domain in that mutations were highly heterogeneous, both within a single cancer tissue and between cancer tissues. We found one double mutant clone, similar to the GAP domain. Of note, no stop mutations were observed. Given the amino terminal location of the GTPase domain, any stop mutations would almost certainly yield inactive protein since it would lack the PH domain. We found only 2 silent mutations, one in a cancer and one from benign tissue. In nine tissues of 35 analyzed (26%) we detected multiple clones containing a previously described silent polymorphism (Rs17852479) at L246 which does not result in any amino acid change. This polymorphism occurs in approximately 28% of individuals in previously studied populations, similar to our finding. A summary of the mutation analysis of GGAP2 is shown in [Table 3](#pone-0032708-t003){ref-type="table"}.

10.1371/journal.pone.0032708.t002

###### Mutation analysis of the GTPase domain of GGAP2 in prostate cancer.

![](pone.0032708.t002){#pone-0032708-t002-2}

  ID       Tissue   Clones   Mutations   Percent                 Missense   mutations  
  ------- -------- -------- ----------- --------- ------------- ---------- ----------- -------
  10764    Cancer     9          4         44         V364A       L239P       P300S     R182G
  6346                10         4         40         E281G       S275P       A198V     S302P
  12161               10         4         40         A173T       N265D       E167K     H117R
  4343                5          2         40         Q115R       L246F                
  8032                9          2         22      H268R/L234P    Q262R                
  7357                10         2         20         R234C       S329N                
  8748                8          2         25         S207N       C200G                
  1954                8          1         12         E332G                            
  3230                7          1         14         K360E                            
  3689                8          1         12         R310G                            
  6882                10         1         10         A292V                            
  9560                7          1         14         S329G                            
  11147               6          1         17         F223L                            
  14198               7          1         14         A175T                            
  15250               7          1         14         K229E                            
  1610     Benign     12         1          8         H117R                            

The GTPase domain was cloned from cDNAs from prostate cancer (\>70% cancer) or benign peripheral zone tissues and sequenced. A total of 23 cancers and 12 benign tissue samples were analyzed. The number of clones is indicated as is the number and percentage of clones with missense mutations. For each individual tissue the missense mutations are shown using the format: normal amino acid/amino acid number in GGAP2/mutant amino acid. Only tissues with missense mutations are shown.

10.1371/journal.pone.0032708.t003

###### Summary of mutation analysis of GAP and GTPase.

![](pone.0032708.t003){#pone-0032708-t003-3}

  [Tissue]{.ul}    [DNA Analyzed]{.ul}   [Number of Tissues]{.ul}   [Total Clones]{.ul}   [Missense/Stop]{.ul}   [Silent]{.ul}
  --------------- --------------------- -------------------------- --------------------- ---------------------- ---------------
  Cancer               GAP (cDNA)                   15                      206                    38                  2
                      GAP (genomic)                 46                      334                    52                  1
                      GTPase (cDNA)                 23                      188                    28                  1

            [DNA Analyzed]{.ul}   [Number of Tissues]{.ul}   [Total Clones]{.ul}   [Missense/Stop]{.ul}   [Silent]{.ul}
  -------- --------------------- -------------------------- --------------------- ---------------------- ---------------
  Benign        GAP (cDNA)                   9                       137                    2                   2
               GAP (genomic)                 22                      167                    1                   0
               GTPase (cDNA)                 12                      88                     1                   1

Summary of mutation analysis of GAP and GTPase clones from cDNA or genomic DNAs from prostate cancer or benign prostate tissues. Does not include the known germline polymorphic loci.

GAP Domain Mutations Increase AP-1 Transcriptional Activity {#s2c}
-----------------------------------------------------------

We have shown that NFκB can increase expression of FOS in prostate cancer cells and thus AP-1 activity [@pone.0032708-Wang2]. To test whether GGAP2 and mutant GGAP2 impacted AP-1 transcription we used site directed mutagenesis to engineer GGAP2 expression constructs containing 9 different missense mutations. These mutant constructs or wild-type or empty vector controls were co-transfected with an AP-1 reporter construct into 293T cells and normalized luciferase activity measured. As shown in [Figure 1](#pone-0032708-g001){ref-type="fig"}, wild type GGAP2 modestly increases AP-1 driven transcription. Multiple mutant clones demonstrated marked enhancement of AP-1 promoter transcription in cells transfected with mutant when compared to wild-type GGAP2 ([Fig. 1](#pone-0032708-g001){ref-type="fig"}).

![GGAP2 mutations result in enhanced transcription from AP-1 reporter constructs.\
Asterisks indicate statistically significant increase relative to wild-type (WT) GGAP2 by ANOVA (p\<.05). Mean +/−SEM. Mutation and number of transfections are shown.](pone.0032708.g001){#pone-0032708-g001}

Association of GAP domain mutations with clinical and pathological parameters of aggressive disease {#s2d}
---------------------------------------------------------------------------------------------------

To determine whether the presence of missense or stop mutations in the GAP domain were associated with aggressive disease we examined in proportion of such mutant clones in prostate cancers with various clinical and pathological parameters associated with aggressive disease ([Figure 2](#pone-0032708-g002){ref-type="fig"}). Early PSA recurrence after radical prostatectomy is associated with death from disease [@pone.0032708-Pound1]. Cancers with early PSA recurrence had 49 mutations among 172 clones analyzed, while cases without early PSA recurrence had only 34 mutations in 234 clones. This difference was statistically significant (p\<0.001, chi sq). Consistent with this, we also found significantly increased proportions of GAP mutations in cases with pelvic lymph node metastasis (p = 0.027, chi sq), seminal vesicle invasion (p = 0.027, chi sq), extracapsular extension (p = 0.015, chi sq) and higher Gleason score (Gleason 5/6 Versus 7--10, p = 0.002, chi sq). These findings strongly support the concept that GAP domain mutations in GGAP2 can promote prostate cancer progression.

![Association of GAP domain mutations with clinical and pathological parameters associated with aggressive prostate cancer.\
The fraction of clones containing missense or stop mutations for cases with each indicated clinical or pathological parameter is shown. All differences between pathological and clinical variables were statistically significant. Specifically: for early PSA recurrence (\<2 years post surgery) versus no or late recurrence (p\<0.001, chi sq); extracapsular extension (ECE) versus no ECE (p = 0.015, chi sq); seminal vesicle invasion (SVI) versus no SVI (p = 0.027, chi sq); pelvic lymph node metastasis (LN) versus no metastasis (p = 0.027, chi sq); Gleason 5/6 versus 7--10 (p = 0.002, chi sq).](pone.0032708.g002){#pone-0032708-g002}

Discussion {#s3}
==========

Clonal mutations in clinically localized prostate cancer are uncommon and usually involve tumor suppressor genes (reviewed in [@pone.0032708-Dong1]). Mutations in oncogenes such as RAS are uncommon in US men with prostate cancer although RAS mutations have been identified more commonly in prostate cancers from Japanese men [@pone.0032708-Dong1]. We have identified frequent mutations of GGAP2 in localized prostate cancer. Overall, half of cancers contained at least one mutant GAP domain clone and in 20% of cancers, 30% or more of clones were mutant in the GAP domain. Surprisingly, while there were 10 different recurrent mutations these only recurred 2--3 times each, overall the GAP domain mutations were heterogeneous and nonclonal. Similar findings were observed in the analysis of the GTPase domain. Multiple lines of evidence argue that these finding are not an artifact including: the rarity of mutation in benign prostate tissues; the dominance of missense mutations in the cancer tissues; the paucity of silent mutations in cancer tissues and the absence of mutations in β-actin.

While both overexpression and nonclonal mutation of GGAP2 are common in prostate cancer the relationship between these two alterations is unclear. Both can potentially activate the siganaling activities of GGAP2 in prostate cancer, although detailed studies would be needed to discern whether these activities are the same for different specific mutations. In some cases overexpression might potentially enhance the biological activities associated with mutation although it is also possible that mutation may compensate for lack of overexpression. Detailed studies of GGAP2 expression, nonclonal mutation and markers of pathway activation in large numbers of tumors will be needed to understand the impact of these distinct alterations in prostate cancer.

Intratumoral genetic heterogeneity involving point mutations of genes such as p53 or K-RAS in different regions of single macroscopic tumors has been noted in cancers such as colon cancer [@pone.0032708-Losi1] and gliomas [@pone.0032708-Ren1]. It should be noted that in our cases all tumors represent a single 6 mm tumor focus and thus our cancers all were from a single tumor focus and is thus the heterogeneity we observed is distinct from this geographic genetic heterogeneity. In our case, the observed heterogeneity reflects heterogeneity at the cellular level within a single tumor focus.

Are the mutations we observed significant? The missense mutation frequency observed in the GAP domain in cancer tissues was 370×10^−6^ per bp sequenced and for the GTPase domain 298×10^−6^ per bp. Bielas et al [@pone.0032708-Bielas1] have shown that the frequency of random mutation in cancer tissues is approximately 2.1×10^−6^ per bp across multiple cancer types. Thus our observed frequency for missense mutation in GGAP2 is 100-fold higher than the background rate of mutation, strongly implying selective growth advantage for the mutant clones. We have also found a significant association between the frequency of mutation in the GAP domain and clinical and pathological parameters associated with aggressive disease, indicating they are clinically significant. It should be noted that in 20% of cases examined that more than 30% of clones from cancer were mutant in the GAP domain. Given that the tissues analyzed were approximately 80% cancer on average, at least 75% of cancer cells would contain a mutant allele (assuming one mutation per cell) in such cases. This is a minimum figure since it does not include GTPase domain mutations and potential mutations in other regions of GGAP2, which have been reported [@pone.0032708-Hu1]. Thus the observed high frequency heterogeneous mutations could contribute directly to local tumor growth in many cases. In addition, the most potent mutations may promote metastasis of specific cellular clones. There is evidence to support the concept that nonclonal p53 mutations in primary prostate cancers can give rise to metastatic lesions [@pone.0032708-Stapleton1]. The high frequency of diverse nonclonal mutations in GGAP2 may provide numerous potential metastatic clones.

Most studies of mutations in cancer have justifiably focused on clonal mutations since it is easier to see the significance of such mutations. Heterogeneous nonclonal mutations will not be detected by many analytical methods or are not further analyzed since it is unclear whether they may be PCR artifacts or simply passenger mutations. Our findings indicate that in some cases high frequency heterogeneous nonclonal mutations can occur and may be clinically important. It remains to be determined how often this is the case with other tumor suppressor genes and oncogenes. In some cases groups have analyzed primary prostate cancers for the presence of mutation using single stranded conformation polymorphism assays followed by sequencing of abnormally migrating bands and found relatively high rates of mutation in some genes. For example, using this approach, mutations in plexin-B1 in were identified in 46% of primary prostate cancers [@pone.0032708-Wong1] but it is difficult to determine the exact percentage of tumor cells in a tumor with that mutation. Given that the mutations are frequent enough to give a distinct band on single stranded conformation polymorphism assays they must be quite frequent although not clonal. This is in contrast to our findings in GGAP2 in which the mutations are highly heterogeneous. Thus variable levels of nonclonal mutations, from highly heterogeneous to oligoclonal may exist in prostate cancer. On the other hand, using an approach similar to ours, Steinkamp et al [@pone.0032708-Steinkamp1] sequenced androgen receptor mRNAs from castrate resistant prostate cancer metastasis. They found high levels of heterogeneity in the mutations with many mutations being present in only 5--10% of clones. This finding is similar to what we observed in GGAP2. The androgen receptor plays a central role in prostate cancer pathogenesis and survival so there is strong selective pressure to retain mutations that lead to activity in the face of anti-androgen therapies. We have shown that GGAP2 is frequently overexpressed in prostate cancer and can activate two key pathways in prostate cancer progression i.e. the NFκB and AKT pathways. In addition, it has a relatively large negative regulatory domain that may be susceptible to disruption, which may make it far easier to activate than some oncogenes such as RAS that require specific point mutations. Additional analyses will be needed to determine the extent to which other genes, including tumor suppressor genes and other oncogenes, have high frequency non-clonal missense or stop mutations.

The potential for high frequency nonclonal mutation adds another layer of complexity to the complex mutational landscape of common cancers that has been revealed by large scale sequencing [@pone.0032708-McLendon1], [@pone.0032708-Ding1], [@pone.0032708-Berger1]. Of note, it has been shown that nonclonal mutations in K-RAS in lung cancer treated with tyrosine kinase inhibitors significantly impact survival [@pone.0032708-Marchetti1]. Thus it will be important to determine the extent to which nonclonal mutations occur across of broad range of genes in prostate and other cancers and whether they impact survival and response to therapy.

Materials and Methods {#s4}
=====================

Human tissue samples {#s4a}
--------------------

Normal peripheral zone and cancer tissues were collected with written informed consent from men undergoing radical prostatectomy by the Baylor College of Medicine Prostate Cancer Program Tissue Bank and snap frozen as described previously [@pone.0032708-Wheeler1]. Patients ranged in age from 43--73 years of age and were predominantly Caucasian. In all cases preoperative imaging and clinical examination revealed clinically localized disease. Pathological staging of radical prostatectomy specimens and pelvic lymph nodes showed approximately 30% Stage 2 (T2N0); 50% Stage 3 (T3N0) and 20% Stage 4 (Any T, N1). All patients provided written informed consent to donate tissues for research and these studies were approved by the Baylor College of Medicine Institutional Review Board. Benign tissues were confirmed to be free of cancer and cancer tissues contained at least 70% carcinoma. RNAs and DNAs were extracted as described previously [@pone.0032708-Wang3], [@pone.0032708-Wang4]. PSA recurrence was defined as serum PSA\>0.2 ng/ml, with early recurrence being recurrence within 2 years of surgery.

Mutation analysis {#s4b}
-----------------

The N-terminal GTPase domain and the C-terminal GAP domain of GGAP2 gene were amplified using PCR and cloned into the PCR 2.1 TOPO vector using TOPO TA cloning kit ( Invitrogen). PCR was performed using Platinum Taq (Invitrogen) to minimize misincorporation. Primers used for cloning were: for GTPase domain Forward: CCGCTCCATTCCTGAACTG; Reverse: GTTGCTGCTTGCGCAAG for the GAP domain: Forward: CACAGACAGCCAAAGCGA; Reverse: CCAAAAGCAGGAGAACGGTAG. DNAs were sequenced in both directions and all base pair changes called by the machine read of the sequence were confirmed by visual examination of sequencing traces. Clones with poor quality sequencing traces were not analyzed. No novel reportable germ line variants were detected.

Site directed mutagenesis {#s4c}
-------------------------

Single nucleotide mutagenesis was carried out according to the manufacturer\'s protocol (Stratagene). Briefly, primers with the target mutations were used in PCR to generate GGAP2 expression constructs containing 9 different missense mutations. Primers used are shown in [Table 4](#pone-0032708-t004){ref-type="table"}. Dpn1enzyme was added to PCR products for 1 h at 37°C to digest template plasmid DNA before the transformation. Clones were sequenced to verify the mutations.

10.1371/journal.pone.0032708.t004

###### Primers for site directed mutagenesis of GGAP2.

![](pone.0032708.t004){#pone-0032708-t004-4}

  ------- ----- --------------------------------
  L233S    For   GAAGGTGGTGACCTCGCGCAAGCAGCAACA
           Rev   TGTTGCTGCTTGCGCGAGGTCACCACCTTC
  S275P    For   CGACTACTCTTCTCCCCTCCCGTCCTCACC
           Rev   GGTGAGGACGGGAGGGGAGAAGAGTAGTCG
  L239P    For     GCCTCTGGCTGCCTGCAAGTCCCTGC
           Rev    CCAGAGGCTGTTGCTGCTTGCGCAAGG
  L643P    For   GCCACGGGAGCTGACCCTGGTGCCGACGGC
           Rev   GCCGTCGGCACCAGGGTCAGCTCCCGTGGC
  V711M    For        CATGGCTACCGTTCTCCTGC
           Rev         CATGTCCTGGGCCTGCAC
  S692G    For         GGGCACCTCGGAGGAGC
           Rev          CCAGCGGCGCCAGGAA
  L624P    For          CCGTCCCGCGTTCGCT
           Rev         CGGGTGTGTGCCCAGGTT
  L643P    For     GCCACGGGAGCTGACCCTGGTGCCG
           Rev     GCCGTCGGCACCAGGGTCAGCTCCC
  Q115R    For   GTTGGTGGATGGACGGACACATCTGGTGCT
           Rev   AGCACCAGATGTGTCCGTCCATCCACCAAC
  ------- ----- --------------------------------

Luciferase transcriptional reporter assays {#s4d}
------------------------------------------

Luciferase transcriptional reporter assays were performed as described previously [@pone.0032708-Wang2] using 293T cells. Both AP-1 luciferase reporter vector and pRL Renilla Luciferase vector were obtained from Stratagene (Cat\# 219077 and \#E2810). The pRL Renilla Luciferase Reporter Vectors are intended for use as an internal control reporters in combination with AP-1 to cotransfect 293T cells. Transient transfection was conducted in triplicate in 24-well plates. Luciferase activity was determined and normalized to Renilla luciferase signal for each sample. Independent assays were performed from 3--9 times.

Statistical analysis {#s4e}
--------------------

To compare rates of mutation between groups chi square or Fisher exact analysis was performed. Luciferase activity of mutant clones was compared using analysis of variance (ANOVA). For all tests p\<.05 was considered significant.
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